Exelixis investor relations material

Exelixis, Inc., is a US-based biotechnology company within oncology. The company focuses on the discovery, development, and commercialization of new medicines to treat cancers in the U.S. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its products also comprise MINNEBRO tablets for the treatment of genetic conditions.